To discuss thrombogenesis risk in patients with coronaryatherosclerotic heart disease of different TCM Syndromes and provide advice for clinical treatment. Methods:The patients (n=173) were chosen and divided into CHD of phlegm and blood stasis group (TYHZ group, n=51), CHD of qistagnancy and blood stasis group (QZXY group, n=55), CHD of qideficiency and blood stasis group (QXXY group, n=42) and CHD of deficiency of both qi and yin group (QYLX group, n=35). All patients were given detection of thromboelastogram and detection of routine haemostatic. Differences in thromboelastogram indexes, coagulation parameters were compared. Results:R level in the four groups were QYLX>QXXY>QZXY>TYHZ,P<0.01; K level in the four groups were QXXY>QYLX, QYLX>QZXY, QYLX>TYHZ, QXXY>QZXY, QXXY>TYHZ, P<0.05; Angle level in the four groups were QZXY>QYLX, TYHZ>QYLX, QZXY>QXXY, TYHZ>QXXY, P<0.05; MA level in the four groups were QZXY>QYLX, TYHZ>QYLX, P<0.05; ADP level in the four groups were QZXY>TYHZ, QZXY>QXXY, P<0.05; PT level in the four groups were QYLX>QXXY, QYLX>QZXY, QYLX＞TYHZ, P<0.05; INR level in the four groups were QYLX>QXXY, QYLX>QZXY, P<0.05; PLT level in the four groups were QXXY>QYLX, QZXY>QYLX, TYHZ>QYLX, TYHZ>QZXY, TYHZ>QYLX, P<0.05; PCT level in the four groups were QXXY>QYLX, YHZ>QYLX, TYHZ>QZXY, TYHZ>QYLX, P<0.05. EPL, LY30, AA, APTT, FIB, PDW, MPV and PLCR showed no significant differences among these four groups, P>0.05. Conclusion:It is significant to evaluate coagulation function of patients with coronaryatheroscleroticheart disease, especially of phlegm and blood stasis, then to apply antiplatelet medicine and to employ the bloodactivating and stasisdispelling herb. This is because these patients are more likely to have thrombogenesis, and it is the effective treatments to reduce the incidence of thrombogenesis.